Cargando…

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS

OBJECTIVES: To assess whether neurofilament light chain (NfL) could serve as an informative endpoint in Phase 2 studies in patients with relapsing–remitting multiple sclerosis (RRMS) and estimate the sample size requirements with NfL as the primary endpoint. METHODS: Using data from the Phase 3 FREE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sormani, Maria Pia, Haering, Dieter A., Kropshofer, Harald, Leppert, David, Kundu, Uma, Barro, Christian, Kappos, Ludwig, Tomic, Davorka, Kuhle, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562031/ https://www.ncbi.nlm.nih.gov/pubmed/31211172 http://dx.doi.org/10.1002/acn3.795

Ejemplares similares

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
por: Kuhle, Jens, et al.
Publicado: (2019)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Long-term prognostic value of longitudinal measurements of blood neurofilament levels
por: Häring, Dieter A., et al.
Publicado: (2020)

Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
por: Reinert, Marie-Christine, et al.
Publicado: (2020)

Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study
por: Tavazzi, Eleonora, et al.
Publicado: (2020)

Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
por: Chitnis, Tanuja, et al.
Publicado: (2018)

Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study
por: Jakimovski, Dejan, et al.
Publicado: (2019)

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
por: Kuhle, Jens, et al.
Publicado: (2021)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Serum neurofilament light chains in MS: Association with the Timed Up and Go
por: Allali, Gilles, et al.
Publicado: (2020)

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

Learning ability correlates with brain atrophy and disability progression in RRMS
por: Sormani, Maria Pia, et al.
Publicado: (2019)

Serum neurofilament light chain as outcome marker for intensive care unit patients
por: Fisse, Anna Lena, et al.
Publicado: (2020)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
por: Disanto, Giulio, et al.
Publicado: (2017)

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2019)

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
por: Gaiottino, Johanna, et al.
Publicado: (2013)

Serum neurofilament light levels in normal aging and their association with morphologic brain changes
por: Khalil, Michael, et al.
Publicado: (2020)

Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury
por: Depoorter, Antoinette, et al.
Publicado: (2018)

Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial
por: Kuhle, Jens, et al.
Publicado: (2023)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Neurofilament light chain level is a weak risk factor for the development of MS
por: Arrambide, Georgina, et al.
Publicado: (2016)

High serum neurofilament associates with diffuse white matter damage in MS
por: Saraste, Maija, et al.
Publicado: (2020)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters
por: Hermesdorf, Marco, et al.
Publicado: (2022)

Development of an age‐adjusted model for blood neurofilament light chain
por: Harp, Christopher, et al.
Publicado: (2022)

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19
por: Ameres, Markus, et al.
Publicado: (2020)

Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2020)

Factors influencing serum neurofilament light chain levels in normal aging
por: Koini, Marisa, et al.
Publicado: (2021)

Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum
por: Herrera-Rivero, Marisol, et al.
Publicado: (2023)

Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome
por: Körtvelyessy, Peter, et al.
Publicado: (2020)

Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
por: Puentes, Fabiola, et al.
Publicado: (2021)

A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies
por: Rübsamen, Nicole, et al.
Publicado: (2022)

Growth differentiation factor 15 is increased in stable MS
por: Amstad, Andrea, et al.
Publicado: (2020)

Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study
por: Rübsamen, Nicole, et al.
Publicado: (2021)

Serum neurofilament light as a biomarker in progressive multiple sclerosis
por: Kapoor, Raju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hsup4k802cv7465t8q3nfqvn2b